US Patent 10,206,877: Scope, Claims, Expiration, and CFTR Formulation Patent Landscape
US Patent No. 10,206,877 protects a specific oral tablet combining amorphous elexacaftor and amorphous ivacaftor in separate polymeric solid dispersions. The core protection is formulation-based, not a broad claim to either active ingredient. The patent is particularly relevant to Vertex Pharmaceuticals’ elexacaftor-containing CFTR modulator products and creates a potential formulation barrier for generic tablets that reproduce the claimed solid-dispersion architecture, dose range, and excipient profile.
The patent issued on February 19, 2019. Public Orange Book data associate the patent with Vertex’s cystic fibrosis products and identify an expiration date in 2037, subject to the applicable patent-term calculation and any terminal-disclaimer or adjustment information recorded by the USPTO.[1-3]
What compounds are protected by US Patent 10,206,877?
Compound 1 is elexacaftor, also known as VX-445. Compound 2 is ivacaftor, also known as VX-770.
| Claim reference |
Compound |
Common name |
Role in CF therapy |
| Compound 1 |
(R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(complex indolyl cyclopropanecarboxamide) |
Elexacaftor, VX-445 |
CFTR corrector |
| Compound 2 |
N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Ivacaftor, VX-770 |
CFTR potentiator |
The patent does not claim elexacaftor or ivacaftor as new chemical entities. Its value comes from the physical form, polymer composition, tablet architecture, dose combination, and cystic-fibrosis treatment methods.
What is the independent composition claim?
Claim 1 requires all of the following:
- A pharmaceutical composition.
- A blend of a first solid dispersion and a second solid dispersion.
- The first solid dispersion contains:
- 70 wt% to 90 wt% amorphous elexacaftor; and
- 10 wt% to 30 wt% hydroxypropyl methylcellulose, or HPMC.
- The second solid dispersion contains:
- 70 wt% to 90 wt% amorphous ivacaftor.
- The composition is a tablet.
- The tablet contains:
- 25 mg to 125 mg elexacaftor; and
- 100 mg to 200 mg ivacaftor.
The claim uses “comprising,” which generally permits additional ingredients and excipients. A tablet can therefore fall within claim 1 even if it contains fillers, disintegrants, lubricants, surfactants, or other formulation components, provided that every required limitation is present.
The claim is narrower than a claim covering any elexacaftor-ivacaftor tablet. A potentially infringing product would need to use amorphous forms of both compounds and the specified separate solid-dispersion arrangement.
What formulations are protected by the dependent claims?
Claims 2 through 17 progressively narrow the formulation.
| Claims |
Added limitation |
Commercial relevance |
| 2-3 |
Ivacaftor dispersion contains 10 wt% to 30 wt% polymer, specifically HPMCAS |
Protects the polymer-assisted ivacaftor dispersion |
| 4 |
Elexacaftor dispersion is 80 wt% elexacaftor and 20 wt% HPMC |
Covers the principal first-dispersion ratio |
| 5 |
Tablet contains 100 mg elexacaftor |
Matches the principal clinical dose |
| 6 |
Tablet contains 150 mg ivacaftor |
Matches the claimed potentiator dose |
| 7-13 |
Filler, disintegrant, and lubricant limitations |
Protects common tablet manufacturing architecture |
| 8-9 |
30 wt% to 50 wt% filler, specifically microcrystalline cellulose |
Narrows the tablet excipient profile |
| 10-11 |
1 wt% to 10 wt% disintegrant, specifically croscarmellose sodium |
Protects disintegration performance and composition |
| 12-13 |
1 wt% lubricant, specifically magnesium stearate |
Covers the tableting lubricant |
| 14-16 |
Absolute excipient amounts |
Creates a second route to infringement based on tablet weight |
| 17 |
Detailed tablet composition |
Closest claim to a defined commercial formulation |
How specific is claim 17?
Claim 17 recites a tablet containing:
- 125 mg of the elexacaftor/HPMC dispersion;
- 187.5 mg of the ivacaftor/HPMCAS/sodium lauryl sulfate dispersion;
- 243.9 mg microcrystalline cellulose;
- 29.6 mg croscarmellose sodium; and
- 5.9 mg magnesium stearate.
The stated active amounts are 100 mg elexacaftor and 150 mg ivacaftor because each solid dispersion is 80 wt% active.
The nominal tablet mass under claim 17 is 591.9 mg:
| Component |
Amount |
| Elexacaftor solid dispersion |
125.0 mg |
| Ivacaftor solid dispersion |
187.5 mg |
| Microcrystalline cellulose |
243.9 mg |
| Croscarmellose sodium |
29.6 mg |
| Magnesium stearate |
5.9 mg |
| Total |
591.9 mg |
Claim 17 is commercially important because it specifies a reproducible manufacturing target rather than only broad concentration ranges.
Does claim 26 contain an inconsistency?
Yes. The supplied text of claim 26 recites 22.9 mg microcrystalline cellulose, while claim 17 recites 243.9 mg. The 22.9 mg value produces a materially different tablet and is inconsistent with the formulation structure otherwise described.
Using 22.9 mg, the claimed tablet mass would be 370.9 mg. Using 243.9 mg, the mass is 591.9 mg. This discrepancy should be checked against the issued patent, certificate of correction, prosecution history, and any later reexamination or post-issuance record before relying on claim 26 in an infringement or validity analysis.
What method-of-use claims does the patent contain?
Claims 18 through 27 protect methods of treating cystic fibrosis rather than the formulation alone.
The method claims require oral administration of the claimed composition or the specifically recited tablet. Dependent claims address:
- once-daily administration;
- once-daily administration followed by 150 mg ivacaftor once daily;
- patients heterozygous for the F508del mutation and a second CFTR mutation;
- patients homozygous for F508del; and
- an increase in chloride transport of at least 10% above baseline.
Claims 21 through 24 identify specific CFTR mutations, including R117H, G551D, G551S, G1244E, S1251N, S1255P, G1349D, G576A, and R668C. These claims align the formulation with genotype-directed CF treatment.
The method claims are narrower than a general claim to treating cystic fibrosis. They require use of the claimed pharmaceutical composition or the specified tablet. A generic product using a different formulation could avoid these claims while still potentially implicating composition claims if its solid dispersions meet the limitations of claim 1 or claim 17.
What is the patent’s technical scope?
The patent addresses formulation problems associated with poorly water-soluble CFTR modulators.
Elexacaftor solid dispersion
The first dispersion requires amorphous elexacaftor and HPMC. The claimed 70 wt% to 90 wt% active range, with 10 wt% to 30 wt% HPMC, is designed to stabilize and improve the dissolution of elexacaftor.
Claim 4 fixes the ratio at 80:20. This limitation is materially stronger against a formulation using the same ratio but may be avoided by changing the polymer, using a crystalline form, or moving outside the claimed concentration range.
Ivacaftor solid dispersion
The second dispersion requires amorphous ivacaftor. Claims 2 and 3 add HPMCAS at 10 wt% to 30 wt%. Claim 17 specifies 80 wt% ivacaftor, 19.5 wt% HPMCAS, and 0.5 wt% sodium lauryl sulfate.
The use of separate dispersions matters. A formulation in which elexacaftor and ivacaftor are co-processed into one dispersion may present a noninfringement position if the product lacks the claimed “first” and “second” solid dispersions. That position would depend on the manufacturing process and the physical characterization of the finished tablet.
How strong is the patent estate?
The patent is strongest against a product that copies the commercial formulation closely.
Strengths
- Claim 1 combines drug identity, amorphous state, dispersion structure, polymer range, dosage form, and active-dose range.
- Claim 4 captures the 80:20 elexacaftor/HPMC ratio.
- Claims 5 and 6 capture the 100 mg elexacaftor and 150 mg ivacaftor amounts.
- Claim 17 provides a highly specific formulation claim that may read directly on a replicated tablet.
- The formulation can be investigated through solid-state analysis, dissolution testing, spectroscopy, and tablet composition testing.
Vulnerabilities
- The claims do not cover all elexacaftor or ivacaftor formulations.
- A competitor may design around the separate-dispersion requirement.
- A crystalline rather than amorphous active form could avoid a central limitation, subject to performance and regulatory requirements.
- Changing HPMC, HPMCAS, concentration ranges, or tablet doses may avoid particular dependent claims.
- The “blend” and solid-dispersion limitations may generate claim-construction disputes where the finished tablet contains multiple particulate phases.
- Method claims may be difficult to enforce against a generic applicant that markets the product for a noninfringing indication or relies on a section viii label carve-out.
Overall, the patent is a strong commercial formulation patent but a weak standalone barrier against every possible elexacaftor- or ivacaftor-containing generic.
What is the Orange Book status of US 10,206,877?
The patent is associated with Vertex Pharmaceuticals’ elexacaftor-containing CFTR products in FDA patent-listing records. The relevant product platform includes Trikafta, which contains elexacaftor, tezacaftor, and ivacaftor, and Alyftrek, which contains vanzacaftor, tezacaftor, and deutivacaftor as of its FDA approval.
The patent’s claim language predates and focuses on an elexacaftor-ivacaftor tablet formulation. Orange Book listing does not establish that every claim reads on every commercial presentation. It gives the listed patent holder a basis to invoke the Hatch-Waxman patent-certification process when an ANDA applicant seeks approval for a listed product.[2]
When does US 10,206,877 lose exclusivity?
The reported patent expiration date is June 16, 2037.[1-3] FDA regulatory exclusivity and patent exclusivity are separate.
| Exclusivity type |
Relevance |
| Patent term |
Reported expiration in 2037 |
| New chemical entity exclusivity |
Not the primary protection at issue for this formulation patent |
| Orphan-drug exclusivity |
Depends on the specific product, indication, and designation |
| Pediatric exclusivity |
May add six months to qualifying periods, if granted |
| Orange Book patent listing |
Supports a Paragraph IV notice and potential litigation |
| Data exclusivity |
Separate from formulation-patent protection |
A generic applicant could potentially file an ANDA before patent expiration with a Paragraph IV certification. Commercial launch would depend on the patent litigation outcome, settlement terms, court relief, and any other listed patents.
Which companies are challenging the patent?
No specific Paragraph IV challenger or settlement should be inferred solely from the patent claims. Public patent risk for Vertex CFTR products is distributed across multiple patents covering compositions, formulations, methods of use, crystalline or amorphous forms, and manufacturing processes.
A generic applicant challenging US 10,206,877 would likely assert one or more of:
- noninfringement based on a different solid-dispersion structure;
- absence of amorphous elexacaftor or ivacaftor;
- different polymer composition;
- different active-dose range;
- lack of enablement;
- lack of written description;
- obviousness over prior solid-dispersion and CFTR-modulator disclosures; or
- indefiniteness involving “blend,” “solid dispersion,” or amorphous-state requirements.
A Paragraph IV challenge to this patent would not necessarily remove all barriers to launch because other Vertex patents may remain enforceable.
Are biosimilar risks relevant?
No. Elexacaftor and ivacaftor are chemically synthesized small molecules, not biologics. The relevant competition is generic or hybrid-drug competition under the ANDA pathway, not biosimilar competition under the Biologics Price Competition and Innovation Act.
The main technical barriers are formulation replication, amorphous-state control, dissolution performance, bioequivalence, and regulatory approval. The patent does not create a biosimilar exclusivity issue.
What generic launch scenarios exist?
Early launch after settlement
A generic company could obtain a license or settlement permitting launch before the reported 2037 expiration date. The commercial terms would depend on the scope of the licensed claims and the remaining Vertex patent estate.
Launch with a formulation design-around
A competitor could pursue a tablet using different polymers, a co-dispersion, a different solid form, or a different dose presentation. This approach would require bioequivalence and adequate dissolution performance.
Launch after successful Paragraph IV litigation
A successful invalidity or noninfringement decision could remove US 10,206,877 as a barrier. Other patents would still require separate analysis.
Delayed launch after patent expiry
A conventional ANDA product could launch after patent expiration if FDA approval, labeling, manufacturing, and remaining listed-patent requirements are satisfied.
How does this patent compare with broader CFTR patents?
US 10,206,877 is narrower than patents claiming the chemical compounds themselves or broad methods of treating CF with CFTR modulators.
| Patent category |
Typical scope |
Relative commercial reach |
| Compound patent |
Chemical structure and salts |
Broadest molecule-level protection |
| Solid-form patent |
Crystalline or amorphous form |
Intermediate |
| Formulation patent |
Dispersion, polymer, tablet, dose |
Narrower but product-specific |
| Method-of-use patent |
Patient genotype, dosing, treatment |
Depends on label and prescribing |
| Manufacturing patent |
Process steps and intermediates |
Relevant if process is copied |
US 10,206,877 has high product specificity. It is most valuable when the marketed tablet uses the claimed 80:20 elexacaftor/HPMC dispersion, 80:19.5:0.5 ivacaftor dispersion, and excipient system.
Key Takeaways
- US 10,206,877 primarily protects a tablet formulation containing amorphous elexacaftor and amorphous ivacaftor in separate solid dispersions.
- Claim 1 requires defined active-content ranges, HPMC in the elexacaftor dispersion, and a tablet dosage form.
- Claims 4 through 17 progressively target the likely commercial formulation, including 100 mg elexacaftor, 150 mg ivacaftor, HPMCAS, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.
- Claims 18 through 27 add cystic-fibrosis treatment, dosing, genotype, and chloride-transport limitations.
- The reported patent expiration date is June 16, 2037.
- The principal competitive threat is an ANDA generic using a formulation design-around, not a biosimilar.
- A generic applicant must evaluate the entire Vertex patent estate because overcoming this patent alone may not enable launch.
- The supplied text contains a material discrepancy in claim 26: 22.9 mg versus 243.9 mg microcrystalline cellulose.
FAQs About US Patent 10,206,877
Does US 10,206,877 claim Trikafta itself?
It does not broadly claim Trikafta or all elexacaftor-containing products. It claims specific tablets and treatment methods involving amorphous elexacaftor and amorphous ivacaftor in defined solid dispersions. Whether a particular Trikafta presentation falls within a claim depends on its formulation and the applicable claim construction.
Can a generic avoid the patent by using crystalline elexacaftor?
Potentially. The independent claims require amorphous elexacaftor. A crystalline formulation may avoid that limitation, but it would need to meet FDA bioequivalence and performance requirements and avoid other Vertex patents.
Does the patent cover ivacaftor alone?
No. The composition claims require a blend containing both the elexacaftor and ivacaftor solid dispersions. The method claims also require the claimed combination or specified tablet.
Is HPMCAS required in every claimed formulation?
No. HPMCAS is required only in dependent claims 3 and 17. Claim 1 requires an ivacaftor solid dispersion but does not expressly require a polymer in that dispersion.
Can changing the tablet excipients avoid infringement?
Changing excipients may avoid claims 7 through 17, but it may not avoid claim 1. Claim 1 permits additional ingredients and focuses on the active dispersions, tablet form, and dose ranges.
References
- United States Patent and Trademark Office. (2019). U.S. Patent No. 10,206,877, pharmaceutical compositions and methods of treatment.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2019). FDA approves new breakthrough therapy for cystic fibrosis.
- Vertex Pharmaceuticals Incorporated. (2024). TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) prescribing information.
